Send Message
View as an RSS Feed
  • 2 Attractive Small Biotech Stocks That Could Become Buyout Targets  [View article]
    Any comments on the DVAX $90 mil stock ATM deal with Cowen ?
    Nov 19, 2015. 11:59 AM | Likes Like |Link to Comment
  • Coca-Cola Will Hit $45 - Cramer's Lightning Round (11/18/15)  [View article]
    Maybe Cramer can get the KO ceo on his show now ! always hunting for guests---if you come on he will push your stock---promise ! he needs guests---his current rotation is awful long in the tooth & needs new blood. Please help him out ! Maybe he'll even put your stock in.......his little action alert fund !!!
    Nov 19, 2015. 09:42 AM | Likes Like |Link to Comment
  • It's Time To Buy Defense Stocks - Cramer's Mad Money (11/18/15)  [View article]
    Cramer---defense stocks are in & up so buy them ! absolutely great analysis from the Rifleman ! give him a chart & he can tell you whether is a buy or a sell----doesn't need to know any more than that !
    Nov 19, 2015. 09:38 AM | 1 Like Like |Link to Comment
  • Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward  [View article]
    You seem to have missed what got ALNY up to an uber-bullish $140/share back in June. It was the enthusiasm & very high hopes that CC5 would be a strong competitor to ALXN's Soliris. The trial results that came in mid-June dramatically dashed those hopes as CC5 was shown to be far short of the high efficacy bar set by Soliris. That alone took major wind out of ALNY story. One would not remotely recognize that from your write-up.
    Nov 14, 2015. 11:55 PM | Likes Like |Link to Comment
  • The Valeant Soap Opera Continues  [View instapost]
    You sound awful nervous about two primarily generics---MYL & TEVA---neither of which ran into much headwinds as you claimed. Relax---neither has a total rollup strategy/no R&D/product price increases like VRX.
    As far as the Senate SPECIAL Committee on Aging---they have limited jurisdiction and naturally are going after the easy headliners like VRX et al. Sen. Claire McCaskill has made it clearly known that she's not going after R&D companies.
    Push DVAX & some of the other names with good near-term stories. Some of the spec early stage clinical names push in the New Year.
    Nov 5, 2015. 09:02 PM | Likes Like |Link to Comment
  • Regeneron Accelerates In Q3: A Review Of The Quarter, The Company, And A Look Ahead  [View article]
    REGN & ALXN have been by far the two monster biotech stocks over the last decade. Yet few in the retail public really knew much about either company surprisingly enough. It must be the complexity of the biotech space. IMO ALXN has the better portfolio to outperform REGN over the next 12-24 months.
    Nov 5, 2015. 10:17 AM | Likes Like |Link to Comment
  • Zafgen Reports Patient Death In Clinical Trial - What It Means For The Equity  [View article]
    How does the FDA putting the trial on partial hold affect your analysis ?
    Oct 16, 2015. 09:36 AM | Likes Like |Link to Comment
  • Premarket Biotech Digest: Alzheimer's Day, Gilead's Conference, Mirna IPO  [View article]
    Do you really think that $400 mil market cap ARWR would be a big deal for $160 Billion cap GILD ??? Really ? The markets would hardly notice this pimple on an elephant's behind----only ARWR holders would.
    Sep 21, 2015. 09:08 AM | 1 Like Like |Link to Comment
  • IBB: Trees Don't Grow To The Sky  [View article]
    You are welcome to your opinion but you really don't know what is actually going on in the drug discovery arena & are quick to generalize about an entire sector as if a broad brush provides sufficient analysis. There are hundreds & hundreds of companies that call themselves biotechs & they sure aren't created equal. Plus the mega-cap pharmas who are starved for innovation & growth have recognized that if you can't discover than buy product. This has been playing out for a number of years & you likely have missed it.
    Investors in healthcare need generalists who don't take the time like you to start with a conclusion & then drum up facts to back it up. Like many Seeking Alpha articles this is submitted for $100 and hardly worth the time it takes to read the article.
    Sep 14, 2015. 08:20 PM | 10 Likes Like |Link to Comment
  • Alexion Pharmaceuticals Will Rise Again  [View article]
    Strange that you make absolutely no comment on the maturing internal pipeline at ALXN. It may be good to read some of the research reports that go into significant detail.
    Aug 24, 2015. 08:59 AM | Likes Like |Link to Comment
  • American Airlines Investors Are Ignoring Major Risks To The Company  [View article]
    This piece is beyond poor. Maybe you're new to the investing game bur AAL is NOT "currently a very popular long" --- having declined over 20% YEAR TO DATE in one of the poorest performing sectors in the market. AAL was a great performer BEFORE the airline space got crowded & provided superior returns. Did you know that ?

    Please keep us posted on "the stock market crash being predicted by almost everyone" ----that is a hoot ! Everyone KNOWS that there is a crash coming ! That's great to know. And finally if AAL is so bad why not short it ??? Please do some homework before posting such gibberish.
    Jun 23, 2015. 06:05 AM | 6 Likes Like |Link to Comment
  • Game Plan For The Week - Cramer's Mad Money (5/29/15)  [View article]
    Sell airlines ??? Buy Buy Buy AAL in the $50s, now sell in the $40s. Cramer does the Chuck Connors Rifleman routine----shoots all over the map. Pity the poor retail investor taking such "guidance".
    Jun 1, 2015. 09:08 AM | 3 Likes Like |Link to Comment
  • Is Tableau Still A Better Investment Than Splunk?  [View article]
    "Value investing" ???? Tableau ? Splunk? looks like you're on the aggressive growth path here----no GARP here.
    May 31, 2015. 03:18 PM | 1 Like Like |Link to Comment
  • Michael Kors: Investors Overreact On Q4 2015 Earnings Release  [View article]
    The fundamentals are very strong ? Is that why the stock has been cut in half ? Which of the last FOUR earnings releases are investors overreacting to ?
    May 28, 2015. 04:19 PM | Likes Like |Link to Comment
  • MEI Pharma To Move Pracinostat Into Phase 3 As Data In Elderly AML Continues To Impress  [View article]
    Cantor Fitzgerald recommends MEIP with a $7 target price.
    May 27, 2015. 09:32 AM | 1 Like Like |Link to Comment